Phase 2 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with, or are strongly suspected by their doctors to have, cancer in the lung, based on a CT scan, biopsy, or other imaging.
- People who are already scheduled to have a keyhole lung surgery (thoracoscopy) to remove part of the lung.
- People who could become pregnant must have a negative pregnancy blood test before the study drug is given, and must be using an accepted form of contraception (such as hormonal birth control or a double-barrier method) or abstaining from sex during the study.
- People who are able to understand what taking part in the study involves.
Who may not be able to join:
- People for whom surgery is not considered safe, or who have a medical condition that the trial doctor believes could put them at risk.
- People who have previously had an allergic or severe reaction to any drug, including reactions to contrast dyes or a dye called indocyanine green (ICG).
- People who have reduced or impaired kidney function.
- People who have a history of significant heart rhythm or electrical problems, or whose heart screening test (ECG) shows any clinically significant abnormality.
- People who have previously had radiation treatment to the chest area.
- People whose liver test results are outside acceptable ranges — specifically, total bilirubin above 1.5 times the normal upper limit, or liver enzyme levels (AST or ALT) more than 2.5 times the normal upper limit (confirm with trial site).
- People who are currently pregnant or breastfeeding.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Robert Honigberg, MD, Integro Theranostics
Phone: 314-779-9620
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Clinically Significant Events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.